Homocysteine and B Vitamins: What the Trials Showed

Homocysteine is the best case study in modern nutrition science of a biomarker that looked causal, generated an entire supplement category, and then failed the trials that were designed to confirm it. It remains genuinely worth measuring in specific circumstances, and the reasons why are more interesting than either the enthusiastic or the dismissive version of the story.

The Biochemistry

Homocysteine is not obtained from food. It is produced endogenously as an intermediate in the metabolism of methionine, an essential amino acid abundant in animal protein. Methionine is activated to S-adenosylmethionine, the universal methyl donor for hundreds of methylation reactions including DNA methylation, neurotransmitter synthesis, creatine synthesis and phosphatidylcholine production. Donating its methyl group converts it to S-adenosylhomocysteine, which is hydrolysed to homocysteine.

From there, two routes. Remethylation regenerates methionine, catalysed by methionine synthase using 5-methyltetrahydrofolate as the methyl donor and vitamin B12 as cofactor, with a parallel betaine-dependent pathway. Transsulfuration commits homocysteine irreversibly to cysteine and ultimately glutathione, via cystathionine beta-synthase, which requires vitamin B6.

Elevated plasma homocysteine therefore indicates that these clearance pathways are not keeping up. The commonest reasons are inadequate folate, B12 or B6 status, impaired renal clearance, hypothyroidism, certain medications, and genetic variation in the enzymes involved, of which the MTHFR C677T polymorphism is the most discussed. High methionine intake from very high animal protein consumption raises the input side, which is directly relevant to people eating three grams of protein per kilogram.

What the Trials Found

The observational case was strong. Elevated homocysteine associated with coronary disease, stroke, venous thromboembolism and dementia across many cohorts. Homocystinuria, a rare genetic disorder producing extreme elevation, causes premature vascular disease, which appeared to establish causality at the extreme.

Then the randomised trials reported. Lonn and colleagues published HOPE-2, randomising over 5,500 patients with vascular disease or diabetes to folic acid with B6 and B12 or placebo for five years. Homocysteine fell substantially in the treatment arm. The primary composite of cardiovascular death, myocardial infarction and stroke was not significantly reduced. Stroke, examined separately, was reduced. Myocardial infarction was not.

Clarke and colleagues subsequently pooled the randomised evidence, covering tens of thousands of participants, and found that lowering homocysteine with B vitamins produced no significant effect on major vascular events, cancer, or all-cause mortality. Their review of the homocysteine-lowering trials reached the same conclusion.

The stroke signal has persisted across several analyses and is the one positive finding with reasonable support, plausibly larger in populations without mandatory folic acid fortification of the food supply. It is a modest effect and it does not rescue the broader hypothesis.

The Cognitive Evidence

The more interesting literature concerns the brain. Douaud and colleagues reported that B vitamin treatment in people with mild cognitive impairment slowed grey matter atrophy in exactly the regions affected in Alzheimer disease, with the effect concentrated in participants with elevated baseline homocysteine. Subsequent analysis from the same programme indicated that the benefit depended on adequate omega-3 fatty acid status, with little effect in those in the lowest tertile.

That interaction is mechanistically coherent. Phosphatidylcholine synthesis via the PEMT pathway is methylation-dependent and is required to incorporate docosahexaenoic acid into membrane phospholipids. Methyl groups without substrate, or substrate without methyl groups, would each be expected to underperform.

This is promising rather than established. The trials are small, the endpoint is imaging rather than clinical dementia, and larger confirmatory work has not delivered a definitive answer. It is the most defensible remaining reason to care about homocysteine, and it should be described as a hypothesis with supportive evidence rather than a demonstrated intervention.

When Measuring Is Actually Useful

The metformin row deserves emphasis given how widely metformin is discussed as a longevity intervention. B12 depletion with long-term use is well established, it can produce neuropathy, and it is easily detected and easily corrected. Anyone taking metformin for years without ever checking B12 status is running an avoidable risk.

On MTHFR: the C677T variant is common, with roughly one in ten people of European ancestry homozygous. Homozygotes have reduced enzyme activity and modestly higher homocysteine. The variant has been commercialised aggressively, with expensive methylfolate products marketed on the basis of a genotype. The evidence that homozygotes derive special benefit from methylfolate over ordinary folic acid, or that the genotype meaningfully changes clinical outcomes in people with adequate folate status, is weak. Adequate folate intake matters; the branded protocol built around the polymorphism generally does not.

What to Take From This

Under the Tony Huge Laws of Biochemistry Physics, this is chain optimisation with the honest ending most people skip. The pathway is real, the cofactors are real, the bottleneck is identifiable, and correcting a genuine deficiency in folate, B12 or B6 is worthwhile and cheap. What the trials showed is that flooding an already-replete system with more cofactor does not deliver additional cardiovascular benefit. Correcting a deficiency is not the same intervention as supplementing beyond sufficiency, and conflating the two is the error that produced twenty years of misplaced confidence.

There is a broader lesson here worth more than the specific finding. Homocysteine had everything: strong observational data, a plausible mechanism, a rare genetic disease supporting causality at the extreme, and a cheap safe intervention. It still failed. That should calibrate how much confidence anyone places in the next biomarker with a compelling story and no outcome trials, and there are a great many of those circulating in this space right now.

Where This Fits in the Bigger Picture

Monitoring is the part of enhancement that nobody posts about, and it is the part that decides how long you get to keep doing this. Testing gives you a feedback loop; without one you are guessing with your organs. Start with the Enhanced Athlete Protocol bloodwork guide, then work through the full protocol hub to see how testing, training, nutrition and recovery connect. If you are early in this, the beginners page is the right entry point.

See the supplements pillar for B vitamin status in context, and the bloodwork guide for how this fits a full panel.

Frequently Asked Questions

What is homocysteine?

Homocysteine is an amino acid produced inside the body during the metabolism of methionine, which comes from dietary protein. It is cleared either by conversion back to methionine, a reaction requiring folate and vitamin B12, or by conversion toward cysteine, which requires vitamin B6. Elevated blood levels usually indicate that one of these pathways is limited, most often by inadequate B vitamin status or reduced kidney clearance.

Do B vitamins lower homocysteine?

Yes, reliably and substantially. Folic acid with vitamin B12 and B6 lowers plasma homocysteine in randomised trials. The important distinction is that lowering the marker did not translate into fewer heart attacks or lower cardiovascular mortality in those trials, although a reduction in stroke was observed in some analyses.

Does high homocysteine cause heart disease?

Observational studies consistently associate elevated homocysteine with cardiovascular disease, but large randomised trials that lowered it with B vitamins failed to reduce myocardial infarction or cardiovascular death. This pattern suggests homocysteine is more a marker of underlying risk and nutritional status than a direct cause at the levels seen in the general population.

Should I get tested for MTHFR?

For most people, routine MTHFR genotyping adds little. The common C677T variant modestly reduces enzyme activity and slightly raises homocysteine, but evidence that carriers require specialised methylfolate products rather than adequate ordinary folate intake is weak. Measuring homocysteine and B vitamin status directly is generally more informative than testing the genotype.

Who should have homocysteine measured?

It is most useful when investigating suspected vitamin B12 deficiency, in people following vegan or vegetarian diets, in long-term metformin users whose B12 absorption may be impaired, in those with unexplained early vascular disease or venous clots, and in the context of cognitive concern with a family history, where B vitamin treatment has shown effects on brain atrophy in specific trial populations.